ArticleHuman vaccines & immunotherapeutics2025

Successes, lessons learned and recommendations for the future: Experiences from the first year of Ontario's nirsevimab program for respiratory syncytial virus (RSV) prophylaxis in infants.

Bosco Paes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.